Cybin (HELP) Cash from Investing Activities (2020 - 2025)
Cybin (HELP) reported Cash from Investing Activities of -$755457.5 for Q1 2025, down 373.48% on a YoY basis from $276238.9 in Q1 2024, and down 248.29% quarter-over-quarter from -$216902.3 in Q4 2024.
Cybin (HELP) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Cybin has reported Cash from Investing Activities for 6 years, with the latest figure at -$755457.5 in Q1 2025.
- For the quarter ending Q1 2025, Cash from Investing Activities fell 373.48% year-over-year to -$755457.5; the trailing twelve-month figure through Mar 2025 stood at -$1.4 million (down 127.49% YoY), and the FY2025 full-year result was -$1.4 million, down 127.53% from the prior year.
- Cash from Investing Activities for Q1 2025 stood at -$755457.5, down from -$216902.3 in the prior quarter.
- The five-year high for Cash from Investing Activities was $5.5 million in Q4 2023, with the low at -$2.1 million in Q1 2022.
- Historically, Cash from Investing Activities has averaged $73314.5 across 5 years, with a median of -$166417.3 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 2835.02% — and 2023, when it soared 3693.26%.
- Cybin's Cash from Investing Activities stood at -$131693.8 in 2021, then fell by 15.8% to -$152497.5 in 2022, then soared by 3693.26% to $5.5 million in 2023, then plunged by 103.96% to -$216902.3 in 2024, then slumped by 248.29% to -$755457.5 in 2025.
- The last three Cash from Investing Activities figures came in at -$755457.5 (Q1 2025), -$216902.3 (Q4 2024), and -$250704.3 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -755,457.46 |
| Mar 31, 2025 | -755,457.46 |
| Dec 31, 2024 | -216,902.29 |
| Dec 31, 2024 | -216,902.29 |
| Sep 30, 2024 | -250,704.27 |
| Sep 30, 2024 | -250,704.27 |
| Jun 30, 2024 | -173,280.31 |
| Jun 30, 2024 | -173,280.31 |
| Mar 31, 2024 | -159,554.34 |
| Mar 31, 2024 | -159,554.34 |
| Dec 31, 2023 | 5.48 Mn |
| Dec 31, 2023 | 5.48 Mn |
| Sep 30, 2023 | -192,450.06 |
| Sep 30, 2023 | -192,450.06 |
| Jun 30, 2023 | -48,389.41 |
| Jun 30, 2023 | -48,389.41 |
| Feb 28, 2023 | 2.31 Mn |
| Feb 28, 2023 | 2.31 Mn |
| Dec 31, 2022 | -152,497.51 |
| Dec 31, 2022 | -152,497.51 |